Conclusions
- Patients with G12D mutations have significantly lower survival compared to G12R.
- Significant molecular differences were seen in MAPK pathway gene expression, markers of immune activation, and genes involved in glucose and glutamine metabolism.
- Metformin use appeared to impact survival in the KRAS G12R subgroup.
- We aim to further explore distinct vulnerabilities based on MAPK pathway activation and dysregulated metabolism.
- Based on this data, future studies should address the KRAS mutation status and explore distinct therapeutic vulnerabilities.